30766-22-4

Basic information

• Product Name: Methyl 5-hydroxynicotinate
• Synonyms: METHYL 5-HYDROXYNICOTINATE;METHYL 5-HYDROXY-3-PYRIDINECARBOXYLATE;5-HYDROXYNICOTINIC ACID METHYL ESTER;5-HYDROXY-3-PYRIDINECARBOXYLIC ACID METHYL ESTER;Hydroxynicotinicacidmethylester;Methyl 5-hydroxypyridine-3-carboxylate;Methyl 5-hydroxynicotinate 98%;Methyl 5-hydroxynicotinate methy ester
• CAS NO: 30766-22-4
• Molecular Formula: C₇H₇NO₃
• Molecular Weight: 153.14
• Product Categories: blocks;Carboxes;Pyridines;Acids and Derivatives;Heterocycles;pharmacetical
• Mol File: 30766-22-4.mol

Chemical Properties

• Melting Point: 190 °C
• Boiling Point: 374.192 °C at 760 mmHg
• Flash Point: 180.105 °C
• Appearance: Light beige/Powder and Lumps
• Density: 1.287 g/cm³
• Vapor Pressure: 3.95E-06mmHg at 25°C
• Refractive Index: 1.551
• Storage Temp.: Keep Cold
• Solubility: DMSO (Heated, Sonicated), Methanol (Slightly, Sonicated)
• PKA: 8.44±0.10(Predicted)
• CAS DataBase Reference: Methyl 5-hydroxynicotinate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 5-hydroxynicotinate(30766-22-4)
• EPA Substance Registry System: Methyl 5-hydroxynicotinate(30766-22-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-41-37/38
• Safety Statements: 26-36/37/39-39-37/39
• WGK Germany: 3
• Hazardous Substances Data: 30766-22-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 5-hydroxynicotinate is used as an intermediate for the preparation of selective cyclooxygenase-2 (COX-2) inhibitors. These inhibitors are important in the development of anti-inflammatory and pain-relieving medications, as they help reduce inflammation and pain without causing the side effects associated with non-selective COX inhibitors.
Additionally, Methyl 5-hydroxynicotinate is used as an intermediate to prepare imino sugars, which act as inhibitors of liver glycogen phosphorylase. This application is significant in the development of treatments for metabolic disorders and conditions related to glucose metabolism, such as diabetes and hypoglycemia.

InChI:InChI=1/C7H7NO3/c1-11-7(10)5-2-6(9)4-8-3-5/h2-4,9H,1H3

Upstream product

• 67-56-1 methanol 
• 27828-71-3 5-hydroxynicotinic acid 
• 958266-11-0 methyl 5-benzyloxy-4-chloronicotinate 
• 29681-44-5 5-bromo-3-pyridine carboxylic acid methyl ester 

Downstream Products

• 323201-20-3 5-oxo-5,6-dihydro-4H-pyridine-1,3-dicarboxylic acid 3-methyl ester 1-phenyl ester 
• 29681-46-7 methyl 5-methoxypyridine-3-carboxylate 
• 227275-04-9 methyl 5-(4-methoxycarbonyl-2-nitrophenoxy)nicotinate 
• 284462-57-3 4-(3-(5-methoxycarbonyl)pyridyloxy)-1-nitrobenzene 
• 847943-53-7 5-hydroxy-nicotinic acid tert-butyl ester 
• 847943-54-8 6-chloro-5-hydroxy-nicotinic acid tert-butyl ester 
• 284462-58-4 methyl 5-(4-aminophenoxy)pyridine-3-carboxylate 
• 20826-03-3 5-methoxypyridine-3-carboxylic acid 
• 298204-74-7 5-(methyloxy)pyridine-3-carbonitrile 
• 177661-64-2 3-methoxy-5-[1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine 
• 862507-05-9 methyl (5-cyclohexyloxy)nicotinate 
• 915107-30-1 methyl 6-chloro-5-hydroxypyridine-3-carboxylate 
• 1055968-94-9 methyl 5-{[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(2-chlorophenyl)propyl]oxy}nicotinate 
• 1055969-09-9 methyl 5-({(2S)-2-[(tert-butoxycarbonyl)amino]-3-[3-(trifluoromethyl)phenyl]propyl}oxy)nicotinate 

Relevant articles and documents

Synthesis and biological evaluation of a series of novel pyridinecarboxamides as potential multi-receptor antipsychotic drugs

In previous study, a series of benzamides was identified as potent antipsychotic agents. As a continuation of the program to discover novel antipsychotics, herein we reported the evaluation of a series of pyridinecarboxamide derivatives. The most promising compound 7h not only held good activities on dopamine D2, serotonin 5-HT1A and 5-HT2A receptors, but also exhibited low potency for α1A, H1 and 5-HT2C receptors, indicating a low propensity of side effects like orthostatic hypotension and weight gain. Furthermore, 7h exhibited more potent antipsychotic-like effect than aripiprazole in behavioral studies. The preliminary results were promising enough for further research around this scaffold.

MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFECTIVE VACCINE ADJUVANT

Disclosed are inhibitors of mevalonate pathway as an efficient vaccine adjuvant and use thereof. In particular, the inhibitor is an acetoacetyl-CoA transferase inhibitor, a HMG-CoA synthase inhibitor, a HMG-CoA reductase inhibitor, a mevalonate kinase inhibitor, a phosphomevalonate kinase inhibitor, a mevalonate-5-pyrophosphate decarboxylase inhibitor, an isopentenyl pyrophosphate isomerase inhibitor, a farnesyl pyrophosphate synthase inhibitor, a geranylgeranyl pyrophosphate synthase inhibitor or a geranylgeranyl transferase (I, II) inhibitor. Also disclosed is an immunogenic composition comprising inhibitors of mevalonate pathway as an adjuvant.

MODIFIED COMPOUND OF ANDROGRAPHOLIDE

The present disclosure discloses a modified compound of andrographolide, and particularly discloses a compound shown in formula (I) and (II) or a pharmaceutically acceptable salt thereof.

BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY

A compound of formula (Ia) or (Ib) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of a histone deacetylase, and as such is useful in terepy, e.g. in the treatment of autoimmune disorders, mental disorders, neurodegenerative disorders, and hyperproliferative disorders.

SUBSTITUTED [1,2,4] TRIAZOLO [1,5-A] PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS

The invention provides a chemical entity of Formula (I): wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of

THERAPEUTIC INHIBITORY COMPOUNDS

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.

BIARYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS

The present invention relates to compounds of the formula (I), wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease ca

Biaryl-propionic acid derivatives and their use as pharmaceuticals

The present invention relates to compounds of the formula I, wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cath

BIARYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS

The present invention relates to compounds of the formula (I), wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease ca

Biaryl-Propionic Acid Derivatives and their Use as Pharmaceuticals

The present invention relates to compounds of the formula I, wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cath